M. Aïoub, F. Lézot, M. Molla, B. Castaneda, B. Robert et al., Msx2 ???/??? transgenic mice develop compound amelogenesis imperfecta, dentinogenesis imperfecta and periodental osteopetrosis, Bone, vol.41, issue.5, pp.851-859, 2007.
DOI : 10.1016/j.bone.2007.07.023

E. R. Barros, G. L. Saraiva, T. P. De-oliveira, and M. Lazaretti-castro, Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta, Journal of Pediatric Endocrinology and Metabolism, vol.25, issue.5-6, pp.485-491, 2012.
DOI : 10.1515/jpem-2012-0016

A. Berdal, B. Castaneda, M. Aïoub, J. R. Néfussi, C. Mueller et al., Osteoclasts in the Dental Microenvironment: A Delicate Balance Controls Dental Histogenesis, Cells Tissues Organs, vol.18, issue.2-4, pp.238-243, 1159.
DOI : 10.1359/jbmr.2003.18.1.108

N. Bishop, S. Adami, S. F. Ahmed, J. Antón, P. Arundel et al., Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial, The Lancet, vol.382, issue.9902, pp.1424-1432, 2013.
DOI : 10.1016/S0140-6736(13)61091-0

F. Bleicher, Odontoblast physiology, Experimental Cell Research, vol.325, issue.2, pp.65-71, 2014.
DOI : 10.1016/j.yexcr.2013.12.012

V. Bradaschia-correa, L. F. Massa, V. E. Arana-chavez, B. Castaneda, Y. Simon et al., Effects of alendronate on tooth eruption and molar root formation in young growing rats, Cell and Tissue Research, vol.228, issue.3, pp.475-485, 2007.
DOI : 10.1177/002215540104900904

B. Castaneda, Y. Simon, J. Jacques, E. Hess, Y. Choi et al., Bone resorption control of tooth eruption and root morphogenesis: Involvement of the receptor activator of NF-??B (RANK), Journal of Cellular Physiology, vol.228, issue.1, pp.74-85, 2011.
DOI : 10.1080/03008200390181753

S. Chawla, R. Henshaw, L. Seeger, E. Choy, J. Blay et al., Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study, The Lancet Oncology, vol.14, issue.9, pp.901-908, 2013.
DOI : 10.1016/S1470-2045(13)70277-8

M. T. Cobourne and P. T. Sharpe, Diseases of the tooth: the genetic and molecular basis of inherited anomalies affecting the dentition, Wiley Interdisciplinary Reviews: Developmental Biology, vol.89, issue.2, pp.183-212, 2013.
DOI : 10.1016/j.ajhg.2011.05.024

T. Cundy, L. Wheadon, and A. King, Treatment of Idiopathic Hyperphosphatasia With Intensive Bisphosphonate Therapy, Journal of Bone and Mineral Research, vol.291, issue.Suppl, pp.703-711, 2004.
DOI : 10.1172/JCI0215952

E. Demir, A. Bereket, B. Ozkan, and M. Topçu, Effect of Alendronate Treatment on the Clinical Picture and Bone Turnover Markers in Chronic Idiopathic Hyperphosphatasia, Journal of Pediatric Endocrinology and Metabolism, vol.42, issue.2, pp.217-221, 2000.
DOI : 10.1007/BF02411260

U. Demirsoy, M. Karadogan, O. Selek, Y. Anik, G. Aksu et al., Golden Bullet???Denosumab, Journal of Pediatric Hematology/Oncology, vol.36, issue.2, pp.156-158, 2014.
DOI : 10.1097/MPH.0000000000000034

V. Duheron, E. Hess, M. Duval, M. Decossas, B. Castaneda et al., Receptor activator of NF-??B (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit, Proceedings of the National Academy of Sciences, vol.99, issue.13, pp.5342-5347, 2011.
DOI : 10.1073/pnas.132636999
URL : https://hal.archives-ouvertes.fr/hal-00579674

N. Federman, E. W. Brien, V. Narasimhan, S. M. Dry, M. Sodhi et al., Giant Cell Tumor of Bone in Childhood: Clinical Aspects and Novel Therapeutic Targets, Pediatric Drugs, vol.31, issue.12, pp.21-28, 2014.
DOI : 10.1200/JCO.2012.46.4255

B. L. Foster, T. E. Popowics, H. K. Fong, and M. J. Somerman, Advances in Defining Regulators of Cementum Development and Periodontal Regeneration, Curr. Top. Dev. Biol, vol.78, issue.06, pp.47-126, 2007.
DOI : 10.1016/S0070-2153(06)78003-6

R. E. Goldsby, T. M. Fan, D. Villaluna, L. M. Wagner, M. S. Isakoff et al., Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: A report from the Children???s Oncology Group, European Journal of Cancer, vol.49, issue.10, pp.2384-2391, 2013.
DOI : 10.1016/j.ejca.2013.03.018

R. L. Grier and G. E. Wise, Inhibition of Tooth Eruption in the Rat by a Bisphosphonate, Journal of Dental Research, vol.19, issue.1, pp.8-15, 1998.
DOI : 10.1007/s004410050561

T. Hiraga, T. Ninomiya, A. Hosoya, H. Nakamura, A. E. Hughes et al., Administration of the bisphosphonate zoledronic acid during tooth development inhibits tooth eruption and formation and induces dental abnormalities in rats. Calcif. Tissue Int Genetic linkage of familial expansile osteolysis to chromosome 18q, Hum. Mol. Genet, vol.86, issue.3, pp.502-510, 1994.

A. Kamoun-goldrat, D. Ginisty, L. Merrer, M. N. Polgreen, L. E. Ogilvie et al., Effects of bisphosphonates on tooth eruption in children with osteogenesis imperfecta, European Journal of Oral Sciences, vol.14, issue.2, pp.195-198, 2008.
DOI : 10.1007/s002230010047

M. Koide, Y. Kobayashi, T. Ninomiya, M. Nakamura, H. Yasuda et al., Osteoprotegerin-Deficient Male Mice as a Model for Severe Alveolar Bone Loss: Comparison With RANKL-Overexpressing Transgenic Male Mice, Endocrinology, vol.154, issue.2, pp.773-7822012, 2013.
DOI : 10.1210/en.2012-1928

F. Lézot, J. Chesneau, S. Battaglia, R. Brion, B. Castaneda et al., Preclinical evidence of potential craniofacial adverse effect of zoledronic acid in pediatric patients with bone malignancies, Bone, vol.68, pp.146-152, 2014.
DOI : 10.1016/j.bone.2014.08.018

F. Lézot, J. Chesneau, B. Navet, B. Gobin, J. Amiaud et al., Skeletal consequences of RANKL-blocking antibody (IK22-5) injections during growth: Mouse strain disparities and synergic effect with zoledronic acid, Bone, vol.73, pp.51-59, 2015.
DOI : 10.1016/j.bone.2014.12.011

F. Lézot, B. L. Thomas, C. Blin-wakkach, B. Castaneda, A. Bolanos et al., Dlx homeobox gene family expression in osteoclasts, Journal of Cellular Physiology, vol.275, pp.779-787, 2010.
DOI : 10.1128/MCB.17.5.2920

C. A. Mitchell, J. G. Kennedy, W. , and R. G. , Dental abnormalities associated with familial expansile osteolysis: a clinical and radiographic study. Oral Surg Cell fate determination during tooth development and regeneration, Oral Med. Oral Pathol. Birth Defects Res. C Embryo Today, vol.70, issue.87, pp.301-307, 1990.
DOI : 10.1016/0030-4220(90)90145-i

M. Molla, V. Descroix, M. Aïoub, S. Simon, B. Castañeda et al., Enamel Protein Regulation and Dental and Periodontal Physiopathology in Msx2 Mutant Mice, The American Journal of Pathology, vol.177, issue.5, pp.2516-2526, 2010.
DOI : 10.2353/ajpath.2010.091224
URL : http://europepmc.org/articles/pmc2966808?pdf=render

K. Nakatsuka, Y. Nishizawa, and S. H. Ralston, Phenotypic Characterization of Early Onset Paget's Disease of Bone Caused by a 27-bp Duplication in the TNFRSF11A Gene, Journal of Bone and Mineral Research, vol.11, issue.8, pp.1381-1385, 2003.
DOI : 10.1359/jbmr.2003.18.8.1381

S. Orestes-cardoso, J. R. Nefussi, F. Lezot, M. Oboeuf, M. Pereira et al., Msx1 Is a Regulator of Bone Formation During Development and Postnatal Growth: In Vivo Investigations in a Transgenic Mouse Model, Connective Tissue Research, vol.125, issue.2-3, pp.153-160, 1080.
DOI : 10.1101/gad.10.11.1382

S. A. Polyzos, A. D. Anastasilakis, I. Litsas, Z. Efstathiadou, M. Kita et al., Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget???s disease, Journal of Bone and Mineral Metabolism, vol.41, issue.suppl 2, pp.706-712, 2010.
DOI : 10.1016/S8756-3282(98)00163-X

S. A. Polyzos, A. D. Anastasilakis, P. Makras, T. , and E. , Abstract, Experimental and Clinical Endocrinology & Diabetes, vol.119, issue.09, pp.519-524, 2011.
DOI : 10.1055/s-0031-1284365

F. Saki, Z. Karamizadeh, S. Nasirabadi, S. Mumm, W. H. Mcalister et al., mutation, Journal of Bone and Mineral Research, vol.11, issue.6, pp.1501-1508, 2013.
DOI : 10.1186/1471-2105-11-548

O. Semler, C. Netzer, H. Hoyer-kuhn, J. Becker, P. Eysel et al., First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI, J. Musculoskelet. Neuronal Interact, vol.12, pp.183-188, 2012.

S. L. Silverman, T. Sousa, V. Bompadre, K. K. White, S. H. Tella et al., Bisphosphonate use in conditions other than osteoporosis Musculoskeletal functional outcomes in children with osteogenesis imperfecta: associations with disease severity and pamidronate therapy Prevention and treatment of postmenopausal osteoporosis, Ann. N.Y. Acad. Sci. J. Pediatr. Orthop. J. Steroid Biochem. Mol. Biol, vol.1218, issue.142, pp.33-37, 2011.

L. M. Ward and F. Rauch, Oral bisphosphonates for paediatric osteogenesis imperfecta?, The Lancet, vol.382, issue.9902, pp.1388-1389, 2013.
DOI : 10.1016/S0140-6736(13)61531-7

M. P. Whyte, Paget's Disease of Bone and Genetic Disorders of RANKL/OPG/RANK/NF-??B Signaling, Annals of the New York Academy of Sciences, vol.53, issue.2, pp.143-164, 2006.
DOI : 10.1056/NEJMoa050893

M. P. Whyte and A. E. Hughes, Expansile Skeletal Hyperphosphatasia Is Caused by a 15-Base Pair Tandem Duplication in TNFRSF11A Encoding RANK and Is Allelic to Familial Expansile Osteolysis, Journal of Bone and Mineral Research, vol.66, issue.Suppl 1, pp.26-29, 2002.
DOI : 10.1007/978-3-662-22505-9_8

L. Widler, K. A. Jaeggi, M. Glatt, K. Müller, R. Bachmann et al., Highly Potent Geminal Bisphosphonates. From Pamidronate Disodium (Aredia) to Zoledronic Acid (Zometa), Journal of Medicinal Chemistry, vol.45, issue.17, pp.3721-3738, 1021.
DOI : 10.1021/jm020819i

G. E. Wise, Cellular and molecular basis of tooth eruption, Orthodontics & Craniofacial Research, vol.87, issue.Suppl 1, pp.67-73, 2009.
DOI : 10.1177/00220345420210040901

P. Zwolak and A. Z. Dudek, Antineoplastic activity of zoledronic acid and denosumab, Anticancer Res, vol.33, pp.2981-2988, 2013.